Crispr Therapeutics Ag Stock Alpha and Beta Analysis
| CRSP Stock | USD 36.99 1.05 2.76% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Crispr Therapeutics AG. It also helps investors analyze the systematic and unsystematic risks associated with investing in Crispr Therapeutics over a specified time horizon. Remember, high Crispr Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Crispr Therapeutics' market risk premium analysis include:
Beta 1.39 | Alpha (0.02) | Risk 3.64 | Sharpe Ratio (0) | Expected Return (0.01) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Crispr |
Crispr Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Crispr Therapeutics market risk premium is the additional return an investor will receive from holding Crispr Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Crispr Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Crispr Therapeutics' performance over market.| α | -0.02 | β | 1.39 |
Crispr Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Crispr Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Crispr Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Crispr Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Crispr Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Crispr Therapeutics shares will generate the highest return on investment. By understating and applying Crispr Therapeutics stock market price indicators, traders can identify Crispr Therapeutics position entry and exit signals to maximize returns.
Crispr Therapeutics Return and Market Media
The median price of Crispr Therapeutics for the period between Sun, Dec 29, 2024 and Sat, Mar 29, 2025 is 41.85 with a coefficient of variation of 7.29. The daily time series for the period is distributed with a sample standard deviation of 3.08, arithmetic mean of 42.28, and mean deviation of 2.15. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 23121 shares by Samarth Kulkarni of Crispr Therapeutics at 55.43 subject to Rule 16b-3 | 12/31/2024 |
2 | 2 Beaten-Down Stocks to Buy Before They Soar by 66 percent and 415, According to Wall Street | 02/24/2025 |
3 | CRISPR Therapeutics Stock Price Down 1.7 percent Whats Next | 03/04/2025 |
4 | Disposition of 190 shares by Bruno Julianne of Crispr Therapeutics at 43.32 subject to Rule 16b-3 | 03/12/2025 |
5 | Samarth Kulkarni Sells 9,973 Shares of CRISPR Therapeutics AG Stock | 03/13/2025 |
6 | CRISPR Therapeutics Among Top Stocks to Buy from Ark Invests Portfolio | 03/18/2025 |
7 | Is CRISPR Therapeutics One of the Most Shorted Stocks in 2025 | 03/19/2025 |
8 | CRISPR Therapeutics AG Declines More Than Market Some Information for Investors | 03/20/2025 |
9 | CRISPR Therapeutics AG Surpasses Market Returns Some Facts Worth Knowing | 03/21/2025 |
10 | CRISPR Therapeutics Upgraded at StockNews.com | 03/24/2025 |
11 | Acquisition by James Kasinger of 18333 shares of Crispr Therapeutics at 49.0 subject to Rule 16b-3 | 03/25/2025 |
12 | CRISPR Therapeutics AG Announces Departure of COO Julianne Bruno | 03/26/2025 |
13 | New light-controlled CRISPR tool enhances precision in genetic research | 03/28/2025 |
About Crispr Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Crispr or other stocks. Alpha measures the amount that position in Crispr Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | |
| Interest Debt Per Share | 3.14 | 3.01 | 2.65 | 1.56 |
| Revenue Per Share | 0.005608 | 4.69 | 0.41 | 0.39 |
Crispr Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Crispr Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Crispr Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Crispr Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Crispr Therapeutics. Please utilize our Beneish M Score to check the likelihood of Crispr Therapeutics' management manipulating its earnings.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Crispr Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.